Company profile: Kymera Therapeutics
1.1 - Company Overview
Company description
- Provider of targeted protein degradation therapeutics, leveraging TPD to eliminate disease-causing proteins, developing investigational degraders KT-474 (IRAK4) in Phase 2 for hidradenitis suppurativa and atopic dermatitis; KT-333 (STAT3) in Phase 1 for hematological malignancies and solid tumors; and KT-253 (MDM2) in Phase 1 for high-grade myeloid malignancies, lymphomas, and solid tumors.
Products and services
- KT-474 (SAR444656): Investigational IRAK4 degrader in Phase 2 clinical trials, degrading IRAK4 to treat immune-inflammatory diseases, specifically hidradenitis suppurativa and atopic dermatitis
- KT-333: Selective degrader of STAT3 in Phase 1 clinical trials for treating hematological malignancies and solid tumors
- KT-253: Investigational degrader targeting MDM2 in Phase 1 clinical trials for high grade myeloid malignancies, lymphomas, and solid tumors
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Kymera Therapeutics
ArriVent BioPharma
HQ: United States
Website
- Description: Provider of pharmaceutical product development to cure presently untreatable cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ArriVent BioPharma company profile →
Secretome Therapeutics
HQ: United States
Website
- Description: Provider of neonatal mesenchymal stem cell-based therapeutics and secretome-based regenerative therapies for heart failure and neurodegenerative and dermatological diseases, including STM-01 for adult and pediatric heart failure and NEO2001 for chronic ischemic heart failure.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Secretome Therapeutics company profile →
Zymeworks
HQ: Canada
Website
- Description: Provider of computational biotechnology for optimizing therapeutic antibodies and other protein-based therapeutics, with a pipeline of bispecific antibodies and antibody-drug conjugates targeting HER2, folate receptor-α, mesothelin, glypican-3, and NaPi2b, including zanidatamab, zanidatamab zovodotin, ZW191, ZW171, ZW251, and ZW220.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Zymeworks company profile →
ImmunoGen
HQ: United States
Website
- Description: Provider of antibody-based anticancer therapeutics using TAP, ELAHERE for platinum-resistant ovarian cancer; investigational IMGN632 for acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm; mirvetuximab soravtansine (monotherapy, with bevacizumab or carboplatin) for platinum-sensitive ovarian cancers; and IMGN151 for recurrent endometrial and high-grade serous epithelial ovarian, primary peritoneal, or fallopian tube cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ImmunoGen company profile →
Normunity
HQ: United States
Website
- Description: Provider of precision immuno-oncology medicines focused on immune normalizers—novel cancer immunotherapies that restore normal immune responses. Includes the Chen Lab Discovery Platform to identify and validate novel targets and Normunity Drug Development to create monoclonal antibodies based on these discoveries.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Normunity company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Kymera Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Kymera Therapeutics
2.2 - Growth funds investing in similar companies to Kymera Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Kymera Therapeutics
4.2 - Public trading comparable groups for Kymera Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →